[dbsights]

> Associations were stronger in men younger than 40 years for all vaccines. In men younger than 40 years old, the number of excess myocarditis events per million people was higher after a second dose of mRNA-1273 than after a positive SARS-CoV-2 test (97 [95% CI, 91–99] versus 16 [95% CI, 12–18]).

> The risk of vaccine-associated myocarditis is consistently higher in younger men, particularly after a second dose of mRNA-1273, where the number of additional events during 28 days was estimated to be 97 per million people exposed. An important consideration for this group is that the risk of myocarditis after a second dose of mRNA-1273 was higher than the risk after infection.

That's from the study you linked; for the group most at risk of vaccine myocarditis, the vaccine was associated with a higher risk than the virus. In this study, this was true for Moderna, with Pfizer being about equivalent risk to the virus (albeit without considering that the risk of infection remains after vaccination). However, there have been other studies that found this to be true for all mrna vaccines.

So to answer your question, its technically true, but only if you dilute the at-risk group by including the entire population.